Our leadership team

Chief Communications & Brand Officer

Kate Dobbs is a collaborative, results-oriented and strategic leader who excels at leading through change and thrives in environments that offer opportunities to build and transform. As Chief Communications & Brand Officer at Solventum, Kate leads the team responsible for brand strategy, media and creative services, executive and internal communications, issues and crisis communications, public relations and enterprise marketing. With more than 25 years of experience across healthcare, pharmaceutical, business-to-business and retail, Kate brings a deep understanding of how to connect with and engage diverse audiences and is known for fostering innovation and developing high-performing teams.  

Prior to Solventum, Kate was Chief Marketing Officer at Interwell Health and Senior Vice President of Marketing & Communications at Fresenius Medical Care, both leaders in the kidney care space. Earlier in her career, Kate was Senior Director of Corporate Communications at Vertex Pharmaceuticals and spent over a decade at Staples in various roles in the U.S. and Europe. 

Chief Strategy & Corporate Development Officer

Rachel Ellingson is a seasoned healthcare executive and former investment banker with more than 30 years of experience, known for her strategy and active portfolio management expertise and ability to build strong, high-impact teams. She brings significant leadership experience having led strategy, M&A and divestiture execution, as well as investor relations and communications in the medtech industry. As Chief Strategy & Corporate Development Officer, she is focused on setting the company’s strategic direction and portfolio transformation roadmap, and executing inorganic actions to drive our long-term growth strategy.

Prior to joining Solventum, Rachel served as Chief Administrative Officer and Chief Strategy Officer at Zimmer Biomet, where she had global oversight of strategy, business development, integration and separation management, as well as marketing and communications. Prior to that, Rachel held similar roles with St. Jude Medical from 2011 through its acquisition by Abbott in 2017. Rachel started her career in investment banking and ultimately rose to Managing Director with Bank of America's Healthcare Investment Banking Group. 

Chief Human Resources Officer

Tammy Gomez is passionate about fostering positive work environments and corporate cultures that put people first and are the most preferred places to work. With more than two decades of human resources experience in the healthcare and health services industry, she leads Solventum’s organisation-wide policies and programmes that attract, support, motivate and develop our team of solvers.

Before joining Solventum, Tammy was Executive Vice President and Chief Human Resource Officer at Owens & Minor. She also spent more than 20 years at Cardinal Health in various roles of increasing responsibility, including most recently leading its Global HR Center of Excellence & HR Services team. She began her career in finance and worked with Prudential and General Motors.

Chief Supply Chain Officer

Paul Harrington is a strategic leader and decisive thinker known for his strong work ethic, global mindset and drive to win. As Chief Supply Chain Officer, Paul oversees Solventum’s plants and distribution centres, while also leading logistics, sourcing, engineering, facilities, real estate and environment, health and safety functions under supply chain. 

Paul has extensive global manufacturing, operations and medtech experience. He spent 10 years at Medtronic where he was most recently Senior Vice President, Global Operations Innovation responsible for shaping, transforming and innovating across the global operations and supply chain function. He also previously served as Vice President Global Operations for the Restorative Therapies Group and Neuromodulation business unit. Prior to joining Medtronic, he was Vice President of Global Manufacturing at Covidien. 

Chief Corporate and Legal Affairs Officer and Company Secretary

Marcela Kirberger is an esteemed global leader in legal, corporate affairs and business, with extensive international experience in healthcare and life sciences.

As Solventum’s Chief Corporate and Legal Affairs Officer and Company Secretary, she spearheads the legal, government affairs, global security and sustainability teams, while also overseeing Solventum’s communications, brand and commercial marketing functions. She is responsible for setting the strategic direction for these areas and managing the company’s global healthcare compliance programme, as well as handling commercial, legal and intellectual property matters.

Before joining Solventum, Marcela served as General Counsel and Company Secretary at Elanco, where she directed the global strategy and operations for legal, government affairs, ESG and Enterprise Risk Management programmes. Her extensive healthcare experience spans US, regional and global leadership roles in consumer health, pharmaceuticals, generics, biotech and medical devices and diagnostics. In this capacity, she held positions at Roche Diagnostics Corporation, Leica Microsystems GmbH (a Danaher company) and various Novartis Group companies. Earlier in her career, she worked as a securities litigator at Lowenstein Sandler in New Jersey.

Chief Commercial Officer

Heather Knight is a strategic and people-first MedTech leader who thrives on building high-performing teams that deliver results. As Chief Commercial Officer at Solventum, Heather oversees global commercial and R&D operations across the company’s MedSurg, Dental Solutions and Health Information Systems segments. She is focused on accelerating growth through coordinated execution, market development and innovation that empowers healthcare professionals and improves patient outcomes. 

Heather brings more than 30 years of experience in the healthcare industry, including leadership roles in general management, upstream innovation and commercial strategy at Baxter, Medtronic, Covidien, Tyco Healthcare and Kendall. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sales across three business segments, as well as R&D, supply chain and medical and regulatory affairs. She also served as interim Group President of Baxter’s Medical Products and Therapies segment, its largest business unit. 

She currently serves on the Board of Directors of Waters Corporation and is deeply committed to mentorship, volunteerism and advancing inclusion and diversity across the industry.

Chief Information & Digital Officer

Amy Landucci is known for building high-performing teams and has a proven track record of delivering digital and technology transformations within healthcare. As Solventum’s Chief Information & Digital Officer, she works closely with the business and technology leaders to create a world-class digital technology platform that carefully aligns to the company’s overall business strategy enabling global operations to accelerate innovation and growth. 

Prior to joining Solventum, Amy was Chief Digital and Technology Officer at Haleon, where she led the technical carveout from GSK to form the world’s largest standalone consumer healthcare company. Prior to GSK, she spent a decade at Novartis in a variety of roles. The first eight years of her career was in consulting with Accenture. Amy has served on the Board of Directors for Healthy Women, the leading independent, non-profit health information source for women in the United States.

Chief Financial Officer

Wayde McMillan is renowned for his financial expertise, profound understanding of the medtech sector and talent for building robust teams. With over 25 years of experience in finance, he has a proven track record of steering profitable growth in dynamic and ever-evolving environments for leading global and innovative enterprises. As the CFO of Solventum, Wayde is dedicated to the company’s mission, strategically positioning Solventum for sustained success, and generating long-term value for shareholders.

Before his tenure at Solventum, Wayde served as Executive Vice President and CFO at the pioneering medical device firm, Insulet. He also previously served as CFO and Vice President of Finance for the $8 billion Minimally Invasive Therapies Group at Medtronic and occupied a variety of leadership roles at Covidien from November 2006 until Medtronic acquired the company in January 2015. Wayde's career began in accounting, audit, financial analysis and investor relations. He currently serves on the Board of Directors of Hologic, Inc.

Senior Vice President, Regulatory Affairs & Quality Assurance

Mike Spears is known for leading organizations that bring innovative products to market, increase customer satisfaction, regulatory compliance, on-time delivery of quality products, and continuous improvements to enhance shareholder value. As Senior Vice President, Regulatory Affairs and Quality Assurance for Solventum, he establishes and delivers quality assurance, regulatory affairs, and compliance strategies, as well as defines and oversees the global quality management system for its worldwide facilities and healthcare-related operations.

Mike has more than 30 years of extensive quality assurance, regulatory and compliance experience with major global medical device companies. Prior to joining Solventum, Mike was Senior Vice President, Regulatory Affairs and Compliance, Insulet Corporation where he provided overall leadership, strategy and management for the development and execution of all worldwide regulatory and compliance issues for its product portfolio. He also held Quality Assurance and Regulatory leadership positions and made an impact at Medtronic, Covidien and Tyco Healthcare.

Chief Transformation Officer

Kathy Weiler is an accomplished executive with a strong track record leading commercial growth and consumer-focused strategies across prominent healthcare and financial services companies for more than 25 years. As Chief Transformation Officer, Kathy is responsible for leading one of the largest transformations within the medtech industry. Kathy will drive change initiatives to evolve Solventum’s operating model and strategy to make an impact on the future direction and performance of the company. She brings more than 25 years of marketing, corporate development, business strategy, product management and customer management experience with top healthcare and finance companies.

Prior to joining Solventum, Kathy was Executive Vice President and Chief Commercial and Growth Officer at Amwell, where she led the company's growth strategy and oversaw business development, sales, account management, marketing and strategic partnerships. Before Amwell, Kathy served as Chief Consumer Officer at Optum, leading the company’s consumerism strategy across the enterprise. She has also held senior leadership roles at UnitedHealth Group, including Chief Consumer Strategy Officer, and Chief Marketing and Experience Officer at Optum Health, where she managed marketing for Optum Care and Population Health Solutions. Earlier in her career, Kathy held leadership positions at Blue Cross and Blue Shield of Massachusetts, Fidelity Investments, BNY Mellon/Pershing and The Hartford. Currently, Kathy serves on the Board of Directors for Axogen.

Former Vice Chairman and Chief Commercial Officer, AbbVie, Inc.

Carlos Albán is an experienced pharmaceutical executive with over 30 years of expertise in global commercial strategy and operations. From December 2018 to March 2021, Mr Albán held the position of Vice Chairman and Chief Commercial Officer at AbbVie, Inc., where he was responsible for global commercial operations, including the commercial functions of Pharmacyclics.

From January 2013 to December 2018, he served as AbbVie’s Executive Vice President of Commercial Operations. Prior to this, from February 2011 to December 2012, Mr Albán was the Senior Vice President of Proprietary Pharmaceutical Products, Global Commercial Operations at Abbott Laboratories, Inc. He previously held several senior roles at Abbott, including Senior Vice President of International Pharmaceuticals from 2009 to 2011, Vice President of Pharmaceuticals for Western Europe and Canada Operations from 2007 to 2009, Vice President of Pharmaceuticals for European Operations from 2006 to 2007, Regional Director for Northern Europe in the international pharmaceutical business from 2004 to 2006 and General Manager of Portugal from 2002 to 2004.

From 1986 to 2002, Mr Albán held various management and leadership roles at Abbott. He also served on the board of SpringWorks Therapeutics, Inc. from 2022 until its acquisition by Merck KGaA in 2025. Mr Albán holds a degree in Economics from Pontificia Universidad Javeriana in Bogotá, Colombia.

Former CEO, Premier Inc.

Susan D. DeVore served as Chief Executive Officer and a member of the Board of Directors at Premier Inc., a leading company in healthcare improvement, from 2013 until May 2021. She also acted as President of Premier from 2013 to April 2019. Ms DeVore continued to serve Premier in a consulting capacity until 2023. Before Premier’s reorganisation, Ms DeVore was President and CEO of Premier Healthcare Solutions, Inc. from 2009 to 2013, and prior to that, she held the position of Chief Operating Officer for several affiliated Premier entities from 2006 to 2009.

Before joining Premier, Ms DeVore accumulated two decades of experience in finance, strategy and healthcare consulting. Additionally, she has been a director at Elevance Health, Inc. since August 2021 and a director at Unum Group since 2018.

Former Partner, EY

From 2002 to 2022, Ms. Edwards distinguished herself as a partner at EY, culminating in her role as Global Client Service Partner from 2017 to 2022. Her career at EY was marked by significant leadership and client service roles, including the stewardship of EY's nearly $4B Assurance practice across 20 countries in the Americas, encompassing 10 regions and a team of over 20,000 professionals. She was instrumental in driving the strategy for audit, forensics, and financial accounting and advisory services throughout the Americas. Beyond her professional achievements, Ms. Edwards has contributed her expertise as a board member and adviser to several esteemed organisations, including the Girl Scouts of the Nation's Capital, Leadership Greater Washington, the Pamplin College of Business Advisory Council at Virginia Tech, and the National Capital Region Advisory Board for the American Red Cross. She holds a Bachelor of Science in Accounting from Virginia Tech.

Special Advisor, Labcorp

Glenn A. Eisenberg held the position of Executive Vice President and Chief Financial Officer at Labcorp Holdings Inc (NYSE: LH), a global life sciences company, from June 2014 until his retirement in December 2024. Subsequently, he served as a special advisor to the CEO until April 2025. Glenn is currently a special advisor and representative on the Synlab Board. Labcorp’s 2025 revenue was $14 billion.

Prior to joining Labcorp, from 2002, he was Executive Vice President of Finance and Administration and Chief Financial Officer at The Timken Company, a global leader in engineered bearings and industrial motion technology.

Before that, he was President and Chief Operating Officer of United Dominion Industries, a diversified industrial manufacturer, which is now a subsidiary of SPX Corporation. In addition, he held several executive roles including Executive Vice President and Chief Financial Officer, and President of its test instrumentation segment.

Mr Eisenberg is currently on the Board of Directors of Lumexa Imaging (NASDAQ: LMRI), MiniMed (NASDAQ: MMED) and Middleby (NASDAQ: MIDD).

He has also served on the public Boards of Directors for the following companies: US Ecology, Inc. until May 2022, where he chaired the Audit Committee; Family Dollar Stores Inc. until July 2015, where he chaired the Audit Committee; Alpha Natural Resources Inc. until May 2015, where he was the lead independent director and chaired the Nominating and Corporate Governance Committee; and Perspecta Inc. until May 2021, where he served on the Audit Committee.

Mr Eisenberg holds a Bachelor of Arts degree from Tulane University and a Master of Business Administration from Georgia State University.

Chief Executive Officer, Solventum

Bryan Hanson has been Chief Executive Officer at Solventum since September 2023 and a member of the Board of Directors since April 2024. Solventum is an independent healthcare company with a valuation of $8.3 billion, boasting a rich history of diverse expertise across the industry – from medical, surgical and dental solutions to health information systems. He leads a dedicated team of 20,000 professionals who work tirelessly every day to deliver better, smarter and safer healthcare, improving lives and shaping the future of health.

Previously known as 3M Health Care, Solventum has an enduring legacy of developing breakthrough solutions to address our customers’ most challenging problems. By pioneering transformative innovations at the convergence of health, material and data science, Solventum advances solutions that positively impact patients’ lives while empowering healthcare professionals to excel. Solventum’s products and services span the healthcare spectrum, uniquely positioning the company to enhance patient experiences, improve outcomes and help reduce the total cost of care while driving long-term value for shareholders.

Bryan is a visionary leader with a passion for transforming and building award-winning organisations. Over his more than 33 year career, he has successfully led, grown and transformed global medical device businesses at Zimmer Biomet, Medtronic and Covidien, achieving greater innovation, commercial success and value for customers, patients and shareholders. He previously served on the board of directors of Walgreens Boots Alliance, Inc.

Chief Executive Officer and Managing Partner, Versalius Ventures, Inc.

Dr. Bernard A. Harris Jr., is chief executive officer and managing partner of Vesalius Ventures, Inc. He served as a trustee/director for Salient and Barings investment funds. He currently serves on the boards of Raytheon Technologies (NYSE: RTX), US Physical Therapy (NYSE: USPH) and MassMutual. He also served as a board member for the National Academies of Science, Engineering and Medicine - Board on Health Sciences Policy, and is currently on the boards of the Texas Medical Centre and the Harris Foundation, which he founded.  Dr. Harris is a former NASA astronaut, has logged more than 438 hours and travelled over 7.2 million miles in space. He was a mission specialist on the space shuttle Columbia in 1993 and a payload commander on space shuttle Discovery in 1995, where he became the first African American to walk in space.  He earned a Bachelor of Science in Biology from the University of Houston, a Master of Medical Science from the University of Texas Medical Branch at Galveston, a Master of Business Administration from the University of Houston – Clear Lake, and a Doctor of Medicine from Texas Tech University Health Sciences Centre School of Medicine. He completed a residency in internal medicine at the Mayo Clinic, a National Research Council Fellowship in endocrinology at the NASA Ames Research Centre and trained as a flight surgeon at the United States Air Force School of Aerospace Medicine. He is a fellow of the American College of Physicians, and a member of the American Academy of Arts and Sciences.

Former EVP and CHRO, Mondelez International, Inc.

Karen J. May, who possesses a unique combination of having been both a financial executive and a human resource executive of global companies, brings to the Board extensive operational, financial and human capital strategy experience. Ms. May has been a member of the board of directors of Ace Hardware Corporation, where she is Chair of the Audit and Finance Committee, since 2017. Since 2019, Ms. May is also a member of the board of directors of Alcon, Inc., where she is chair of the Compensation Committee.  Previously, Ms. May was on the board of directors of MB Financial, Inc., where she served as Chair of the Compensation Committee until 2019. From 2012 to 2018, she was the Executive Vice President and Chief Human Resources Officer at Mondelez International, Inc. From 2005 to 2012, Ms. May was the Executive Vice President and Chief Human Resources Officer of Kraft Foods, Inc. Between 1990 and 2005, she held various positions in Human Resources and Finance at Baxter International Inc., including Corporate Vice President and Chief Human Resources Officer, Vice President, International Finance, and Vice President, Division Controller. Prior to Baxter International Inc., Ms. May was a Certified Public Accountant in the audit practice of Price Waterhouse.

Chief Executive Officer, The T1D Fund

Elizabeth A. Mily is a 30+ year healthcare and financial industry veteran, serving most recently as the Executive Vice President, Strategy & Business Development, at Bristol-Myers Squibb.  In this role, she oversaw the company strategy and approach to sourcing external innovation, including all business development activities, strategic partnerships, alliance management, mergers and acquisitions, and the company’s broad equity investing portfolio. Elizabeth was appointed to the position in March 2020. Prior to joining Bristol-Myers Squibb, Elizabeth was a senior member of the Global Healthcare Group at Barclays where she led its Lifesciences business, including the BioPharma, Life Science Tools and Diagnostics sectors.  Prior to joining Barclays, Elizabeth served as Senior Vice President, Corporate Strategy and Development at Thermo Fisher Scientific. Before Thermo Fisher, Elizabeth spent 16 years at Goldman, Sachs & Co., where she was a Managing Director and senior coverage officer within the Healthcare Department of the Investment Banking Division.  Elizabeth holds a Master of Science in Foreign Service from Georgetown University and a Bachelor of Arts in German Literature and European History from the Ohio State University.  She was also a Fulbright Scholar to the Universities of Cologne and Hamburg, Germany.  Prior to attending University, Elizabeth completed a Congress-Bundestag scholarship to Germany.  Elizabeth previously served on the Dean’s Advisory Council of the Ohio State University Fisher College of Business and previously served as a Trustee of the Stephen Gaynor School.

Former President and COO, C.R. Bard, Inc.

John H. Weiland served as President and Chief Operating Officer of medical device company C. R. Bard, Inc. from 2003 until 2017, when Bard was acquired by Becton, Dickinson and Company. He also served on Bard’s board of directors from 2005 to 2017, becoming Vice Chairman of the Board in 2016. Mr. Weiland joined Bard in 1996 and held the position of Group President, with global responsibility for several Bard divisions and its worldwide manufacturing operations prior to becoming President and Chief Operating Officer. Prior to Bard, he held senior management positions at Dentsply International, American Hospital Supply, Baxter Healthcare, and Pharmacia AB. Mr. Weiland served on the board of Cardinal Health, Inc. from 2019 to 2022, where he chaired the Risk Oversight Committee. He also brings valuable perspectives and insights from his prior service on the boards of directors of Celgene Corporation, including service on its Audit Committee, and West Pharmaceutical Services’ board of directors, including chairing its Compensation and Finance Committees.

Former Senior Vice President, Strategy, Business Development and Licensing, Covidien

Amy A. Wendell served as a Senior Advisor for Perella Weinberg Partners’ Healthcare Investment Banking Practice from 2016 to 2019. In this role, she provided guidance and advice on mergers, acquisitions and divestitures for clients, and assisted the firm with transactions at the firm level. From 2015 to September 2018, Ms Wendell was a Senior Advisor for McKinsey’s Strategy and Corporate Finance Practice, and also served on McKinsey’s Transactions Advisory Board identifying and defining trends in mergers and acquisitions and shaping McKinsey’s knowledge agenda.

From 1986 until January 2015, Ms Wendell held various roles with increasing responsibility at Covidien plc (including its predecessors Tyco Healthcare and Kendall Healthcare Products), spanning engineering, product management and business development. Most recently, from December 2006 until Covidien’s acquisition by Medtronic plc in January 2015, she was the Senior Vice President of Strategy and Business Development. In this role, she led the company’s strategy and portfolio management initiatives and oversaw all business development activities, including acquisitions, equity investments, divestitures and licensing/distribution.

Ms Wendell is a Director at AxoGen, Inc., where she is a member of the Audit Committee and Chairperson of the Compensation Committee; at Baxter International, Inc., where she serves on the Quality, Compliance and Technology Committee and the Compensation and Human Capital Committee; and at Hologic, Inc., where she is the Lead Director, a member of the Compensation Committee and Chairperson of the Nominating and Governance Committee. Additionally, she has served on the board of Por Cristo, a non-profit charitable medical service organisation that provides healthcare for at-risk women and children in Latin America. Ms Wendell holds a Bachelor of Science in Mechanical Engineering from Lawrence Technological University and a Master of Science in Biomedical Engineering from the University of Illinois.

Former Vice President, Commercial, GE Power, General Electric Company

Darryl Wilson is a strategic business executive who has built highly successful organisations and led complex business transformations at General Electric and British Petroleum businesses around the world for more than 35 years. Darryl was a Vice President and Corporate Officer of the General Electric Company. After leaving GE in 2017, Darryl founded The Wilson Collective, an investment and business advisory firm that advises, consults and invests in a portfolio of businesses. He serves on the NextEra Energy Board of Directors, Audit and Compensation Committees and also serves on the Eaton Corporation Board of Directors, Audit and Governance Committees. He was recently appointed to the Primerica Board of Directors. He served as Chairman of the Board of the Dallas Federal Reserve - Houston Branch; Houston Endowment - Finance and Investment Committees; Texas Children's Hospital - Finance and Public Policy Committees; The Kinkaid School Board of Trustees - Finance and Endowment Committees. Darryl also served on the Dallas Federal Reserve Board, Energy Advisory Committee. Darryl held P&L leader roles based internationally in Canada; Budapest, Hungary; London, England and Shanghai, China. He held CEO roles in Asia Pacific, Europe, Middle East and Africa for GE Consumer and Industrial. He served as President & CEO of GE Aero Derivatives Energy, a global aircraft engine technology business and also served as President & CEO GE Consumer Products EMEA. In his final GE position, Darryl was Vice President, Commercial in the GE Power division, leading global sales and marketing for a $38B provider of power generation, transmission, distribution and services. Darryl joined GE in 1992, after earning an MBA in Marketing from Indiana University. He has a BA in Business Administration from Baldwin Wallace College in Ohio and spent the first six years of his career in the Executive Development Programme at British Petroleum North America in Cleveland, Ohio. He has been active in many other community organisations; Darryl is a former Board Member and Executive Committee Member of the Greater Houston Partnership, The Houston Food Bank, The American Heart Association, The Dream Foundation, The East End Neighbourhood Centre and The Greater Cleveland Urban League. Darryl also served on several corporate boards representing General Electric affiliates, and joint ventures internationally. He was appointed by GE and the US Government to the US and Mexico Energy council.